Latest Articles

  • Update on antiobesity pharmacotherapy in adults: Current and emerging options
    Farah Ziyadeh, MD, Sara Saliba, MD, RD, Dania Salih Bacha, MD, Yael Mauer, MD, MPH, Marcio L. Griebeler, MD, DABOM and Bartolome Burguera, MD, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 36-46; DOI: https://doi.org/10.3949/ccjm.93a.24112

    The authors review antiobesity medications that are currently available or under investigation and discuss how to personalize obesity treatment.

  • A young woman with Kallmann syndrome and acute neurologic symptoms
    A young woman with Kallmann syndrome and acute neurologic symptoms
    Jumaina F. Ali, MBChB, Adhithya Sankar, MBChB, PhD, Mohammed S. O. Ahmed, MBBS, MSc, Mark Woodward, BSc (Hons), MBChB and Akheel A. Syed, MBBS, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 29-34; DOI: https://doi.org/10.3949/ccjm.93a.25010

    Diagnoses considered on initial presentation included conditions that present with stroke-like symptoms such as seizure, hemiplegic migraine, transient ischemic attack, and brain tumor.

  • Vaccine hesitancy: Where are we heading?
    Sherif Beniameen Mossad, MD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 21-26; DOI: https://doi.org/10.3949/ccjm.93a.25104

    Vaccination recently was hailed as one of the top 10 public health achievements of the 20th century; now, the World Health Organization lists vaccine hesitancy among the top 10 threats to global health.

  • Multicentric reticulohistiocytosis
    Atul Khasnis, MD, MS and Joseph M. Dyer, DO
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 9-11; DOI: https://doi.org/10.3949/ccjm.93a.24124

    A 58-year-old man presented with a 2-month history of joint pain and swelling and a rash.

  • Atrial fibrillation in patients with obesity: How can we optimize management?
    Asim Kichloo, MD, Ivan Magallanes Marrufo, MPH and Suhaib Andrabi, MD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 17-20; DOI: https://doi.org/10.3949/ccjm.93a.25032

    Heart rate and rhythm control therapies often must be adjusted when treating patients with obesity, while other measures can reduce the onset or recurrence of atrial fibrillation.

  • Do corticosteroids prevent reactions to infusions of contrast, monoclonal antibodies, or chemotherapy?
    CME article
    Dylan T. Timberlake, MD, Sushmitha Boppana, MD and James Fernandez, MD, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 47-53; DOI: https://doi.org/10.3949/ccjm.93a.25026

    The data and recommendations about corticosteroid pretreatment vary by medication class and the individual medication, necessitating a medication- and patient-specific approach.

  • Skin manifestations of mpox
    James Kim, MD, Matt Biondi, MD and Helen Bartels, MB, BChir
    Cleveland Clinic Journal of Medicine December 2025, 92 (12) 736-737; DOI: https://doi.org/10.3949/ccjm.92a.25022

    The patient presented with a tender, ulcerated perianal lesion and scattered papules on the trunk and extremities.

  • In Reply: Corticosteroids in severe community-acquired pneumonia
    Alejandro Chapa-Rodriguez, MD, Tark Abou-Elmagd, MD, Cody O’Rear, DO and Shraddha Narechania, MD
    Cleveland Clinic Journal of Medicine December 2025, 92 (12) 724; DOI: https://doi.org/10.3949/ccjm.92c.12006
  • How can I select the right thyroid hormone formulation for my patient with hypothyroidism?
    Lea El Hage, MD and Vinni Makin, MBBS, MD
    Cleveland Clinic Journal of Medicine December 2025, 92 (12) 745-747; DOI: https://doi.org/10.3949/ccjm.92a.25042

    Knowing the features of the available thyroid hormone formulations can provide a starting point for individualizing therapy for patients who have concerns about product formulations or remain symptomatic despite a normal thyroid-stimulating hormone level.

  • LADA: A case for starting insulin therapy at diagnosis
    Byron J. Hoogwerf, MD
    Cleveland Clinic Journal of Medicine December 2025, 92 (12) 764-766; DOI: https://doi.org/10.3949/ccjm.92a.25084

    The author discusses factors that support starting insulin therapy at diagnosis in all patients with latent autoimmune diabetes in adults.

Pages